These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37267191)

  • 21. Buprenorphine Medication for Opioid Use Disorder: A Study of Factors Associated With Postpartum Treatment Retention.
    Ray-Griffith S; Tharp E; Coker JL; Catlin D; Knight B; Stowe ZN
    Am J Addict; 2021 Jan; 30(1):43-48. PubMed ID: 32673447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. College students' perceived knowledge of and perceived helpfulness of treatments for opioid use disorder at two American universities.
    Andraka-Christou B; Nguyen T; Harris S; Madeira J; Totaram R; Randall-Kosich O; Atkins D; Ford J
    Am J Drug Alcohol Abuse; 2020 Sep; 46(5):589-603. PubMed ID: 32543922
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use Disorder.
    Randall-Kosich O; Andraka-Christou B; Totaram R; Alamo J; Nadig M
    J Addict Med; 2020; 14(4):e44-e52. PubMed ID: 31651562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
    Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
    J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
    Biondi BE; Vander Wyk B; Schlossberg EF; Shaw A; Springer SA
    Addict Sci Clin Pract; 2022 Mar; 17(1):15. PubMed ID: 35255967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial.
    Socias ME; Wood E; Le Foll B; Lim R; Choi JC; Mok WY; Bruneau J; Rehm J; Wild TC; Bozinoff N; Hassan A; Jutras-Aswad D;
    Addiction; 2022 Oct; 117(10):2662-2672. PubMed ID: 35712892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spatial and Nonspatial Factors Associated with Access to Medication for Opioid Use Disorder among Pregnant Women in Massachusetts.
    Joshi C; Ho Chui KK; Skeer MR; Stopka TJ
    Subst Use Misuse; 2022; 57(13):1904-1917. PubMed ID: 36219099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder.
    Schiff DM; Nielsen TC; Hoeppner BB; Terplan M; Hadland SE; Bernson D; Greenfield SF; Bernstein J; Bharel M; Reddy J; Taveras EM; Kelly JF; Wilens TE
    Am J Obstet Gynecol; 2021 Oct; 225(4):424.e1-424.e12. PubMed ID: 33845029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. United States county jail treatment and care of pregnant incarcerated persons with opioid use disorder.
    Benck KN; Seide K; Jones AK; Omori M; Rubinstein LB; Beckwith C; Nowotny KM
    Drug Alcohol Depend; 2023 Jun; 247():109863. PubMed ID: 37071946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stigmatization of medications for opioid use disorder in 12-step support groups and participant responses.
    Andraka-Christou B; Totaram R; Randall-Kosich O
    Subst Abus; 2022; 43(1):415-424. PubMed ID: 34214400
    [No Abstract]   [Full Text] [Related]  

  • 31. Health professionals' attitudes toward medications for opioid use disorder.
    Brown AR
    Subst Abus; 2022; 43(1):598-614. PubMed ID: 34520703
    [No Abstract]   [Full Text] [Related]  

  • 32. "Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness.
    Swartz N; Adnan T; Peréa F; Baggett TP; Chatterjee A
    J Subst Abuse Treat; 2022 Jul; 138():108752. PubMed ID: 35277306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. "Will My Baby Be OK?" A Qualitative Analysis of Pregnant Women's Suboxone
    Moore DJ; Butzlaff A
    J Am Psychiatr Nurses Assoc; 2023; 29(3):185-193. PubMed ID: 37038973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of naltrexone in treating opioid use disorder in pregnancy.
    Towers CV; Katz E; Weitz B; Visconti K
    Am J Obstet Gynecol; 2020 Jan; 222(1):83.e1-83.e8. PubMed ID: 31376396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medications for opioid use disorder in pregnancy in a state women's prison facility.
    Knittel AK; Zarnick S; Thorp JM; Amos E; Jones HE
    Drug Alcohol Depend; 2020 Sep; 214():108159. PubMed ID: 32683223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prescribed and Penalized: The Detrimental Impact of Mandated Reporting for Prenatal Utilization of Medication for Opioid Use Disorder.
    Work EC; Muftu S; MacMillan KDL; Gray JR; Bell N; Terplan M; Jones HE; Reddy J; Wilens TE; Greenfield SF; Bernstein J; Schiff DM
    Matern Child Health J; 2023 Dec; 27(Suppl 1):104-112. PubMed ID: 37253899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychometric evaluation of two indices assessing stigma toward opioid misuse and treatment among health care providers.
    Brown RL; Batty E; Lofwall M; Kiviniemi M; Kizewski A
    Am J Drug Alcohol Abuse; 2022 Mar; 48(2):158-164. PubMed ID: 35100062
    [No Abstract]   [Full Text] [Related]  

  • 38. Attitudes toward medications for opioid use disorder among peer recovery specialists.
    Pasman E; Lee G; Singer S; Burson N; Agius E; Resko SM
    Am J Drug Alcohol Abuse; 2024 May; 50(3):391-400. PubMed ID: 38640497
    [No Abstract]   [Full Text] [Related]  

  • 39. Disparities in receipt of medications for opioid use disorder among pregnant women.
    Henkhaus LE; Buntin MB; Henderson SC; Lai P; Patrick SW
    Subst Abus; 2022; 43(1):508-513. PubMed ID: 34270396
    [No Abstract]   [Full Text] [Related]  

  • 40. Prescribing and Acceptance of Medications for Opioid Use Disorder in VA Primary Care: Veteran and Provider Perspectives.
    Bergman AA; Oberman RS; Taylor SL; Kranke B; Chang ET
    J Gen Intern Med; 2024 Jul; 39(9):1690-1697. PubMed ID: 38587730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.